Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

ZJYL vs DBVT vs MPWR vs ALKS vs INVA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ZJYL
Jin Medical International Ltd.

Medical - Instruments & Supplies

HealthcareNASDAQ • CN
Market Cap$344M
5Y Perf.-70.5%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.+18.3%
MPWR
Monolithic Power Systems, Inc.

Semiconductors

TechnologyNASDAQ • US
Market Cap$77.41B
5Y Perf.+214.9%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+25.6%
INVA
Innoviva, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.93B
5Y Perf.+102.7%

ZJYL vs DBVT vs MPWR vs ALKS vs INVA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ZJYL logoZJYL
DBVT logoDBVT
MPWR logoMPWR
ALKS logoALKS
INVA logoINVA
IndustryMedical - Instruments & SuppliesBiotechnologySemiconductorsBiotechnologyBiotechnology
Market Cap$344M$1712.35T$77.41B$5.90B$1.93B
Revenue (TTM)$43M$0.00$2.79B$1.56B$424M
Net Income (TTM)$5M$-168M$616M$153M$504M
Gross Margin35.8%55.2%65.4%76.2%
Operating Margin10.0%26.1%12.3%14.8%
Forward P/E93.6x73.1x24.8x11.9x
Total Debt$12M$22M$24M$70M$269M
Cash & Equiv.$8M$194M$1.10B$1.12B$551M

ZJYL vs DBVT vs MPWR vs ALKS vs INVALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ZJYL
DBVT
MPWR
ALKS
INVA
StockMar 23May 26Return
Jin Medical Interna… (ZJYL)10029.5-70.5%
DBV Technologies S.… (DBVT)100118.3+18.3%
Monolithic Power Sy… (MPWR)100314.9+214.9%
Alkermes plc (ALKS)100125.6+25.6%
Innoviva, Inc. (INVA)100202.7+102.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: ZJYL vs DBVT vs MPWR vs ALKS vs INVA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: INVA leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Monolithic Power Systems, Inc. is the stronger pick specifically for growth and revenue expansion and dividend income and shareholder returns. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
ZJYL
Jin Medical International Ltd.
The Healthcare Pick

ZJYL plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
DBVT
DBV Technologies S.A.
The Income Pick

DBVT is the clearest fit if your priority is income & stability.

  • Dividend streak 0 yrs, beta 1.26
Best for: income & stability
MPWR
Monolithic Power Systems, Inc.
The Growth Play

MPWR is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 26.4%, EPS growth -65.2%, 3Y rev CAGR 15.9%
  • 24.9% 10Y total return vs INVA's 94.9%
  • 26.4% revenue growth vs DBVT's -100.0%
  • 0.4% yield; 8-year raise streak; the other 4 pay no meaningful dividend
Best for: growth exposure and long-term compounding
ALKS
Alkermes plc
The Quality Angle

Among these 5 stocks, ALKS doesn't own a clear edge in any measured category.

Best for: healthcare exposure
INVA
Innoviva, Inc.
The Defensive Pick

INVA carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and valuation efficiency.

  • Lower volatility, beta 0.13, Low D/E 22.9%, current ratio 14.64x
  • PEG 1.15 vs ZJYL's 4.48
  • Beta 0.13, current ratio 14.64x
  • Lower P/E (11.9x vs 24.8x)
Best for: sleep-well-at-night and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthMPWR logoMPWR26.4% revenue growth vs DBVT's -100.0%
ValueINVA logoINVALower P/E (11.9x vs 24.8x)
Quality / MarginsINVA logoINVA118.9% margin vs DBVT's 0.3%
Stability / SafetyINVA logoINVABeta 0.13 vs MPWR's 2.28
DividendsMPWR logoMPWR0.4% yield; 8-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)MPWR logoMPWR+148.6% vs ZJYL's -86.4%
Efficiency (ROA)INVA logoINVA32.4% ROA vs DBVT's -89.0%

ZJYL vs DBVT vs MPWR vs ALKS vs INVA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ZJYLJin Medical International Ltd.

Segment breakdown not available.

DBVTDBV Technologies S.A.

Segment breakdown not available.

MPWRMonolithic Power Systems, Inc.
FY 2023
DC To DC Products
94.4%$1.7B
Lighting Control Products
5.6%$102M
ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
INVAInnoviva, Inc.
FY 2025
Royalty
57.5%$236M
Product
41.8%$172M
License And Other Revenue
0.7%$3M

ZJYL vs DBVT vs MPWR vs ALKS vs INVA — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMPWRLAGGINGALKS

Income & Cash Flow (Last 12 Months)

INVA leads this category, winning 4 of 6 comparable metrics.

MPWR and DBVT operate at a comparable scale, with $2.8B and $0 in trailing revenue. INVA is the more profitable business, keeping 118.9% of every revenue dollar as net income compared to ALKS's 9.8%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricZJYL logoZJYLJin Medical Inter…DBVT logoDBVTDBV Technologies …MPWR logoMPWRMonolithic Power …ALKS logoALKSAlkermes plcINVA logoINVAInnoviva, Inc.
RevenueTrailing 12 months$43M$0$2.8B$1.6B$424M
EBITDAEarnings before interest/tax$5M-$112M$781M$212M$86M
Net IncomeAfter-tax profit$5M-$168M$616M$153M$504M
Free Cash FlowCash after capex-$581,373-$151M$664M$392M$181M
Gross MarginGross profit ÷ Revenue+35.8%+55.2%+65.4%+76.2%
Operating MarginEBIT ÷ Revenue+10.0%+26.1%+12.3%+14.8%
Net MarginNet income ÷ Revenue+10.9%+22.1%+9.8%+118.9%
FCF MarginFCF ÷ Revenue-1.4%+23.8%+25.1%+42.8%
Rev. Growth (YoY)Latest quarter vs prior year-6.4%+20.8%+28.2%+10.6%
EPS Growth (YoY)Latest quarter vs prior year-105.3%+91.5%-88.4%-4.1%+4.0%
INVA leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

INVA leads this category, winning 4 of 7 comparable metrics.

At 6.9x trailing earnings, INVA trades at a 94% valuation discount to MPWR's 123.6x P/E. Adjusting for growth (PEG ratio), INVA offers better value at 0.67x vs ZJYL's 4.48x — a lower PEG means you pay less per unit of expected earnings growth.

MetricZJYL logoZJYLJin Medical Inter…DBVT logoDBVTDBV Technologies …MPWR logoMPWRMonolithic Power …ALKS logoALKSAlkermes plcINVA logoINVAInnoviva, Inc.
Market CapShares × price$344M$1712.35T$77.4B$5.9B$1.9B
Enterprise ValueMkt cap + debt − cash$348M$1712.35T$76.3B$4.9B$1.7B
Trailing P/EPrice ÷ TTM EPS93.62x-0.76x123.60x24.76x6.91x
Forward P/EPrice ÷ next-FY EPS est.73.12x11.91x
PEG RatioP/E ÷ EPS growth rate4.48x4.19x0.67x
EV / EBITDAEnterprise value multiple87.30x97.90x17.25x8.10x
Price / SalesMarket cap ÷ Revenue14.65x27.74x4.00x4.55x
Price / BookPrice ÷ Book value/share12.06x0.66x21.56x3.28x1.65x
Price / FCFMarket cap ÷ FCF116.20x12.28x9.88x
INVA leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

MPWR leads this category, winning 4 of 9 comparable metrics.

INVA delivers a 46.5% return on equity — every $100 of shareholder capital generates $46 in annual profit, vs $-130 for DBVT. MPWR carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to ZJYL's 0.41x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs ZJYL's 2/9, reflecting strong financial health.

MetricZJYL logoZJYLJin Medical Inter…DBVT logoDBVTDBV Technologies …MPWR logoMPWRMonolithic Power …ALKS logoALKSAlkermes plcINVA logoINVAInnoviva, Inc.
ROE (TTM)Return on equity+16.9%-130.2%+17.9%+8.8%+46.5%
ROA (TTM)Return on assets+9.7%-89.0%+15.2%+5.4%+32.4%
ROICReturn on invested capital+10.3%+22.2%+18.9%+14.2%
ROCEReturn on capital employed+13.8%-145.7%+20.4%+14.2%+12.4%
Piotroski ScoreFundamental quality 0–924675
Debt / EquityFinancial leverage0.41x0.13x0.01x0.04x0.23x
Net DebtTotal debt minus cash$3M-$172M-$1.1B-$1.0B-$282M
Cash & Equiv.Liquid assets$8M$194M$1.1B$1.1B$551M
Total DebtShort + long-term debt$12M$22M$24M$70M$269M
Interest CoverageEBIT ÷ Interest expense20.63x-189.82x32.30x63.45x
MPWR leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

MPWR leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in MPWR five years ago would be worth $46,617 today (with dividends reinvested), compared to $2,767 for ZJYL. Over the past 12 months, MPWR leads with a +148.6% total return vs ZJYL's -86.4%. The 3-year compound annual growth rate (CAGR) favors MPWR at 56.1% vs ZJYL's -26.8% — a key indicator of consistent wealth creation.

MetricZJYL logoZJYLJin Medical Inter…DBVT logoDBVTDBV Technologies …MPWR logoMPWRMonolithic Power …ALKS logoALKSAlkermes plcINVA logoINVAInnoviva, Inc.
YTD ReturnYear-to-date-51.1%+4.9%+68.5%+25.3%+14.7%
1-Year ReturnPast 12 months-86.4%+110.4%+148.6%+16.5%+21.7%
3-Year ReturnCumulative with dividends-60.7%+19.7%+280.3%+14.5%+95.2%
5-Year ReturnCumulative with dividends-72.3%-69.1%+366.2%+60.9%+94.4%
10-Year ReturnCumulative with dividends-72.3%-87.0%+2494.7%-11.0%+94.9%
CAGR (3Y)Annualised 3-year return-26.8%+6.2%+56.1%+4.6%+25.0%
MPWR leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ALKS and INVA each lead in 1 of 2 comparable metrics.

INVA is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than MPWR's 2.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs ZJYL's 12.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricZJYL logoZJYLJin Medical Inter…DBVT logoDBVTDBV Technologies …MPWR logoMPWRMonolithic Power …ALKS logoALKSAlkermes plcINVA logoINVAInnoviva, Inc.
Beta (5Y)Sensitivity to S&P 5001.57x1.26x2.28x1.06x0.13x
52-Week HighHighest price in past year$18.00$26.18$1662.00$36.60$25.15
52-Week LowLowest price in past year$0.12$7.53$613.00$25.17$16.52
% of 52W HighCurrent price vs 52-week peak+12.2%+76.3%+94.8%+96.7%+90.7%
RSI (14)Momentum oscillator 0–10053.748.171.060.239.9
Avg Volume (50D)Average daily shares traded22K252K577K2.3M621K
Evenly matched — ALKS and INVA each lead in 1 of 2 comparable metrics.

Analyst Outlook

MPWR leads this category, winning 1 of 1 comparable metric.

Analyst consensus: DBVT as "Buy", MPWR as "Buy", ALKS as "Buy", INVA as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 2.5% for MPWR (target: $1615). MPWR is the only dividend payer here at 0.37% yield — a key consideration for income-focused portfolios.

MetricZJYL logoZJYLJin Medical Inter…DBVT logoDBVTDBV Technologies …MPWR logoMPWRMonolithic Power …ALKS logoALKSAlkermes plcINVA logoINVAInnoviva, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$46.33$1615.00$44.00$37.67
# AnalystsCovering analysts15252810
Dividend YieldAnnual dividend ÷ price+0.4%
Dividend StreakConsecutive years of raises0800
Dividend / ShareAnnual DPS$5.90
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.0%+0.5%+0.2%
MPWR leads this category, winning 1 of 1 comparable metric.
Key Takeaway

MPWR leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). INVA leads in 2 (Income & Cash Flow, Valuation Metrics). 1 tied.

Best OverallMonolithic Power Systems, I… (MPWR)Leads 3 of 6 categories
Loading custom metrics...

ZJYL vs DBVT vs MPWR vs ALKS vs INVA: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ZJYL or DBVT or MPWR or ALKS or INVA a better buy right now?

For growth investors, Monolithic Power Systems, Inc.

(MPWR) is the stronger pick with 26. 4% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ZJYL or DBVT or MPWR or ALKS or INVA?

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus Monolithic Power Systems, Inc. at 123. 6x. On forward P/E, Innoviva, Inc. is actually cheaper at 11. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innoviva, Inc. wins at 1. 15x versus Monolithic Power Systems, Inc. 's 2. 48x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — ZJYL or DBVT or MPWR or ALKS or INVA?

Over the past 5 years, Monolithic Power Systems, Inc.

(MPWR) delivered a total return of +366. 2%, compared to -72. 3% for Jin Medical International Ltd. (ZJYL). Over 10 years, the gap is even starker: MPWR returned +24. 9% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ZJYL or DBVT or MPWR or ALKS or INVA?

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Monolithic Power Systems, Inc. 's 2. 28β — meaning MPWR is approximately 1707% more volatile than INVA relative to the S&P 500. On balance sheet safety, Monolithic Power Systems, Inc. (MPWR) carries a lower debt/equity ratio of 1% versus 41% for Jin Medical International Ltd. — giving it more financial flexibility in a downturn.

05

Which is growing faster — ZJYL or DBVT or MPWR or ALKS or INVA?

By revenue growth (latest reported year), Monolithic Power Systems, Inc.

(MPWR) is pulling ahead at 26. 4% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, MPWR leads at 15. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ZJYL or DBVT or MPWR or ALKS or INVA?

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ZJYL or DBVT or MPWR or ALKS or INVA more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Innoviva, Inc. (INVA) is the more undervalued stock at a PEG of 1. 15x versus Monolithic Power Systems, Inc. 's 2. 48x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Innoviva, Inc. (INVA) trades at 11. 9x forward P/E versus 73. 1x for Monolithic Power Systems, Inc. — 61. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

08

Which pays a better dividend — ZJYL or DBVT or MPWR or ALKS or INVA?

In this comparison, MPWR (0.

4% yield) pays a dividend. ZJYL, DBVT, ALKS, INVA do not pay a meaningful dividend and should not be held primarily for income.

09

Is ZJYL or DBVT or MPWR or ALKS or INVA better for a retirement portfolio?

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Monolithic Power Systems, Inc. (MPWR) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +94. 9%, MPWR: +24. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ZJYL and DBVT and MPWR and ALKS and INVA?

These companies operate in different sectors (ZJYL (Healthcare) and DBVT (Healthcare) and MPWR (Technology) and ALKS (Healthcare) and INVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ZJYL is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; MPWR is a mid-cap high-growth stock; ALKS is a small-cap quality compounder stock; INVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ZJYL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 6%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

MPWR

High-Growth Quality Leader

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Net Margin > 13%
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

INVA

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 71%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.